Explain the biologic rationale and mechanism of action underlying the efficacy of ADCs targeting HER2, HER3, TROP-2, and c-Met for the treatment of NSCLC Evaluate available efficacy and safety findings of approved and investigational ADCs indicated for the treatment of NSCLC Apply the latest evidence, guidelines, and expert recommendations to make treatment selections for patients with NSCLC, including the optimal placement of ADCs within evolving treatment paradigms Implement multidisciplinary strategies to monitor, proactively identify, and treat adverse events associated with ADCs in the community and VA healthcare settings
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2025-01-01 06:00:00
- End Date: 2025-01-01 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 25000.0 - Is Kind Support: False
- Activity Type: Live Course
- CME Finder Type: Conference
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all